Changing faces, unmasking the beta-cell: Post-translational modification of antigens in type 1 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 4, 2013, Pages 299-306

  Van Lummel, Menno ^a   Zaldumbide, Arnaud ^a   Roep, Bart O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

beta cell stress; human leucocyte antigen; islet antigens; post translational modification; type 1 diabetes

Indexed keywords

ANTIGEN; AUTOANTIGEN; AUTOREACTIVITY; BIOLOGICAL MARKER; EPITOPE; LEUKOCYTE ANTIGEN; UNCLASSIFIED DRUG;

AUTOIMMUNITY; BINDING AFFINITY; CELL STRESS; DISEASE PREDISPOSITION; ENDOPLASMIC RETICULUM STRESS; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; THYMUS; TRANSLATION REGULATION;

ANIMALS; ANTIGENS; DIABETES MELLITUS, TYPE 1; ENDOPLASMIC RETICULUM; HUMANS; INSULIN-SECRETING CELLS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84880274758     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283631417     Document Type: Review

References (77)

1. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:51-60.
2. Roep BO, Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 2010; 10: 145-152.
3. Roep BO. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 1996; 45:1147-1156.
4. Eizirik DL, Sammeth M, Bouckenooghe T, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012; 8:e1002552.
5. Dogra RS, Vaidyanathan P, Prabakar KR, et al. Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas. Diabetologia 2006; 49:953-957.
6. Diez J, Park Y, Zeller M, et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes 2001; 50:895-900.
7. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009; 136:777-793.
8. Ortis F, Naamane N, Flamez D, et al. Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells. Diabetes 2010; 59:358-374.
9. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5:219-226.
10. Gurzov EN, Barthson J, Marhfour I, et al. Pancreatic beta-cells activate a JunB/ATF3-dependent survival pathway during inflammation. Oncogene 2012; 31:1723-1732.
11. Cnop M, Foufelle F, Velloso LA. Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med 2012; 18:59-68.
12. Eizirik DL, Miani M, Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 2013; 56:234-241.
13. Dunne JL, Overbergh L, Purcell AW, Mathieu C. Posttranslational modifications of proteins in type 1 diabetes: the next step in finding the cure? Diabetes 2012; 61:1907-1914.
14. Kopito RR, Ron D. Conformational disease. Nat Cell Biol 2000; 2:E207-E209.
15. Marhfour I, Lopez XM, Lefkaditis D, et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia 2012; 55:2417-2420.
16. Bachar-Wikstrom E, Wikstrom JD, Ariav Y, et al. Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes 2012.
17. Bachar-Wikstrom E, Wikstrom JD, Kaiser N, et al. Improvement of ER stress-induced diabetes by stimulating autophagy. Autophagy 2013; 9:.
18. Hasnain SZ, Lourie R, Das I, et al. The interplay between endoplasmic reticulum stress and inflammation. Immunol Cell Biol 2012; 90:260-270.
19. Tang C, Koulajian K, Schuiki I, et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. Diabetologia 2012; 55:1366-1379.
20. Negi S, Park SH, Jetha A, et al. Evidence of endoplasmic reticulum stress mediating cell death in transplanted human islets. Cell Transplant 2012; 21:889-900.
21. Lei X, Zhang S, Bohrer A, et al. Role of calcium-independent phospholipase A(2)beta in human pancreatic islet beta-cell apoptosis. Am J Physiol En-docrinol Metab 2012; 303:E1386-E1395.
22. Wang M, Crager M, Pugazhenthi S. Modulation of apoptosis pathways by oxidative stress and autophagy in beta cells. Exp Diabetes Res 2012; 2012:647914.
23. Fonseca SG, Burcin M, Gromada J, Urano F. Endoplasmic reticulum stress in beta-cells and development of diabetes. Curr Opin Pharmacol 2009; 9:763-770.
24. Delong T, Baker RL, He J, et al. Diabetogenic T-Cell clones recognize an altered peptide of chromogranin A. Diabetes 2012.
25. Ko SH, Ryu GR, Kim S, et al. Inducible nitric oxide synthase-nitric oxide plays an important role in acute and severe hypoxic injury to pancreatic beta cells. Transplantation 2008; 85:323-330.
26. Yang SN, Berggren PO. Beta-cell CaV channel regulation in physiology and pathophysiology. Am J Physiol Endocrinol Metab 2005; 288:E16-E28.
27. Mutskov V, Felsenfeld G. The human insulin gene is part of a large open chromatin domain specific for human islets. Proc Natl Acad Sci USA 2009; 106:17419-17424.
28. Lubec B, Hermon M, Hoeger H, Lubec G. Aromatic hydroxylation in animal models of diabetes mellitus. FASEB J 1998; 12:1581-1587.
29. Kowluru A, Veluthakal R, Rhodes CJ, et al. Protein farnesylation- dependent Raf/extracellular signal-related kinase signaling links to cytoskeletal remodeling to facilitate glucose-induced insulin secretion in pancreatic beta-cells. Diabetes 2010; 59:967-977.
30. Mustafa I, Ahmad S, Dixit K, et al. Glycated human DNA is a preferred antigen for anti-DNA antibodies in diabetic patients. Diabetes Res Clin Pract 2012; 95:98-104.
31. Strollo R, Rizzo P, Spoletini M, et al. HLA-dependent autoantibodies against posttranslationally modified collagen type II in type 1 diabetes mellitus. Diabetologia 2013; 56:563-572.
32. Ahmed N, Babaei-Jadidi R, Howell SK, et al. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005; 48:1590-1603.
33. Marzban L, Soukhatcheva G, Verchere CB. Role of carboxypeptidase E in processing of pro-islet amyloid polypeptide in {beta}-cells. Endocrinology 2005; 146:1808-1817.
34. Mannering SI, Harrison LC, Williamson NA, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 2005; 202:1191-1197.
35. Doyle HA, Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol 2012; 24:112-118.
36. Doyle HA, Mamula MJ. Posttranslational protein modifications in antigen recognition and autoimmunity. Trends Immunol 2001; 22:443-449.
37. Skowera A, Ellis RJ, Varela-Calvino R, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118:3390-3402.
38. Stadinski BD, Delong T, Reisdorph N, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11:225-231.
39. Thorsby E, Ronningen KS. Particular HLA-DQ molecules play a dominant role in determining susceptibility or resistance to type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36:371-377.
40. Eerligh P, van Lummel M, Zaldumbide A, et al. Functional consequences of HLA-DQ8 homozygosity versus heterozygosity for islet autoimmunity in type 1 diabetes. Genes Immun 2011.
41. Nepom BS, Nepom GT, Coleman M, Kwok WW. Critical contribution of beta chain residue 57 in peptide binding ability of both HLA-DR and-DQ molecules. Proc Natl Acad Sci USA 1996; 93:7202-7206.
42. Liu GY, Fairchild PJ, Smith RM, et al. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995; 3:407-415.
43. van Lummel M, van Veelen PA, Zaldumbide A, et al. The type 1 diabetes associated HLA-DQ8-transdimer accomodates a unique peptide repertoire. J Biol Chem 2011.
44. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleio-tropic functions. Nat Rev Mol Cell Biol 2003; 4:140-156.
45. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002; 27:534-539.
46. Rodolfo C, Mormone E, Matarrese P, et al. Tissue transglutaminase is a multifunctional BH3-only protein. J Biol Chem 2004; 279:54783-54792.
47. Zemskov EA, Janiak A, Hang J, et al. The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 2006; 11:1057-1076.
48. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011; 13:184-190.
49. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response. Amino Acids 2007; 33:385-394.
50. Milakovic T, Tucholski J, McCoy E, Johnson GV. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 2004; 279:8715-8722.
51. Kuo TF, Tatsukawa H, Matsuura T, et al. Free fatty acids induce transglutaminase 2-dependent apoptosis in hepatocytes via ER stress-stimulated PERK pathways. J Cell Physiol 2012; 227:1130-1137.
52. Kooy-Winkelaar Y, van Lummel M, Moustakas AK, et al. Gluten- specificTcells cross-react between HLA-DQ8 and the HLA-DQ2{alpha}/DQ8{beta} trans-dimer. J Immunol 2011.
53. Zemskov EA, Mikhailenko I, Hsia RC, et al. Unconventional secretion of tissue transglutaminase involves phospholipid-dependent delivery into recycling endosomes. PLoS One 2011; 6:e1 9414.
54. Caputo I, Secondo A, Lepretti M, et al. Gliadin peptides induce tissue transglutaminase activation and ER-stress through Ca2+ mobilization in Caco-2 cells. PLoS One 2012; 7:e45209.
55. Matic I, Sacchi A, Rinaldi A, et al. Characterization of transglutaminase type II role in dendritic cell differentiation and function. J Leukoc Biol 2010; 88:181-188.
56. Hodrea J, Demeny MA, Majai G, et al. Transglutaminase 2 is expressed and active on the surface of human monocyte-derived dendritic cells and macrophages. Immunol Lett 2010; 130:74-81.
57. Ireland JM, Unanue ER. Processing of proteins in autophagy vesicles of antigen-presenting cells generates citrullinated peptides recognized by the immune system. Autophagy 2012; 8:429-430.
58. Ansari NA, Moinuddin F, Ali R. Glycated lysine residues: a marker for none-nzymatic protein glycation in age-related diseases. Dis Markers 2011; 30:317-324.
59. Khan MW, Sherwani S, Khan WA, Ali R. Characterization of hydroxyl radical modified GAD65: a potential autoantigen in type 1 diabetes. Autoimmunity 2009; 42:150-158.
60. Trigwell SM, Radford PM, Page SR, et al. Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus. Clin Exp Immunol 2001; 126:242-249.
61. Nepom GT. MHC class II tetramers. J Immunol 2012; 188:2477-2482.
62. James EA, Moustakas AK, Bui J, et al. HLA-DR1 001 presents 'altered-self peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum 2010; 62:2909-2918.
63. Raki M, Fallang LE, Brottveit M, et al. Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients. Proc Natl Acad Sci USA 2007; 104:2831-2836.
64. Snir O, Rieck M, Gebe JA, et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011; 63:2873-2883.
65. Pinkse GG, Tysma OH, Bergen CA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005; 102:18425-18430.
66. Velthuis JH, Unger WW, Abreu JR, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010; 59:1721-1730.
67. Abreu JR, Martina S, Verrijn Stuart AA, et al. CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clin Exp Immunol 2012; 170:57-65.
68. Scotto M, Afonso G, Osterbye T, et al. HLA-B7-restricted islet epitopes are differentially recognized in type 1 diabetic children and adults and form weak peptide-HLA complexes. Diabetes 2012; 61:2546-2555.
69. Alleva DG, Gaur A, Jin LA, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) pep-tide. Diabetes 2002; 51:2126-2134.
70. Geluk A, van Meijgaarden KE, Roep BO, Ottenhoff TH. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes. J Autoimmun 1998; 11:353-361.
71. Gebe JA, Masewicz SA, Kochik SA, et al. Inhibition of altered peptide ligand-mediated antagonism of human GAD65-responsive CD4\+ T cells by non-antagonizable T cells. Eur J Immunol 2004; 34:3337-3345.
72. van Aalst D, Kalbacher H, Palesch D, et al. A proinsulin 74-90-derived protease-resistant, altered peptide ligand increases TGF-beta 1 secretion in PBMC from patients with type 1 diabetes mellitus. J Leukoc Biol 2010; 87:943-948.
73. Alleva DG, Maki RA, Putnam AL, et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 2006; 63:59-69.
74. Walter M, Philotheou A, Bonnici F, et al. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009; 32:2036-2040.
75. Zhu Q, Zhong JJ, Jin JF, et al. Tauroursodeoxycholate, a chemical chaperone, prevents palmitate-induced apoptosis in pancreatic beta-cells by reducing ER stress. Exp Clin Endocrinol Diabetes 2013; 121:43-47.
76. Herchuelz A, Nguidjoe E, Jiang L, Pachera N. Beta-cell preservation and regeneration in diabetes by modulation of beta-cell Ca(2)(\+) homeostasis. Diabetes Obes Metab 2012; 14 (Suppl 3):136-142.
77. McKimpson WM, Weinberger J, Czerski L, et al. The apoptosis inhibitor ARC alleviates the ER stress response to promote beta-cell survival. Diabetes 2013; 62:183-193.